- Home
- AVA vs AKRO Comparison
AVA vs AKRO Comparison
Compare AVA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVA
- AKRO
- Stock Information
- Founded
- AVA 1889
- AKRO 2017
- Country
- AVA United States
- AKRO United States
- Employees
- AVA N/A
- AKRO N/A
- Industry
- AVA Power Generation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- AVA Utilities
- AKRO Health Care
- Exchange
- AVA Nasdaq
- AKRO Nasdaq
- Market Cap
- AVA 3.0B
- AKRO 3.6B
- IPO Year
- AVA N/A
- AKRO 2019
- Fundamental
- Price
- AVA $36.06
- AKRO $42.85
- Analyst Decision
- AVA Hold
- AKRO Strong Buy
- Analyst Count
- AVA 1
- AKRO 8
- Target Price
- AVA $39.00
- AKRO $80.38
- AVG Volume (30 Days)
- AVA 575.8K
- AKRO 871.2K
- Earning Date
- AVA 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- AVA 5.42%
- AKRO N/A
- EPS Growth
- AVA N/A
- AKRO N/A
- EPS
- AVA 2.24
- AKRO N/A
- Revenue
- AVA $1,955,000,000.00
- AKRO N/A
- Revenue This Year
- AVA $4.08
- AKRO N/A
- Revenue Next Year
- AVA $4.21
- AKRO N/A
- P/E Ratio
- AVA $16.12
- AKRO N/A
- Revenue Growth
- AVA 2.44
- AKRO N/A
- 52 Week Low
- AVA $34.80
- AKRO $21.34
- 52 Week High
- AVA $43.09
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- AVA 39.76
- AKRO 35.10
- Support Level
- AVA $35.95
- AKRO $42.56
- Resistance Level
- AVA $36.55
- AKRO $45.44
- Average True Range (ATR)
- AVA 0.46
- AKRO 1.77
- MACD
- AVA -0.02
- AKRO -0.21
- Stochastic Oscillator
- AVA 9.48
- AKRO 14.90
About AVA Avista Corporation
Avista Corp is an electric and natural gas utility company. The company has two business segments including Avista Utilities, which provides electric distribution and transmission, and natural gas distribution services in parts of eastern Washington and northern Idaho, and also provides natural gas distribution service in parts of northeastern and southwestern Oregon. Avista Utilities has electric generating facilities in Washington, Idaho, Oregon, and Montana. AEL&P is a regulated utility providing electric services in Juneau, Alaska that is a wholly-owned subsidiary and the primary operating subsidiary of AERC.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.